Index
thyroiditis
(C o n tin u e d )
hypertrophic lymphocytic, 639
juvenile lymphocytic, 639
Riedel's disease, 638-639
silent (subacute lymphocytic), 637-638
subacute granulomatous of De Quervain, 637
thyroid-suppressive therapy, 965-966
TIS
see
ThinPrep Imaging System
TNM (tumor-node metastasis) criteria, 434
toluidine blue stain
bladder cancer screening, 409
effusions, 518, 519
TOP2A gene, 1081
Torulopsis g lab rata,
fungal infection, 122
toxic chemicals, cellular changes induced by, 315
toxic nodular hyperplasia, thyroid gland, 643
toxic shock (micrococcus vaginitis), 97
transitional cell carcinoma
bladder cancer, 446
lung cancer,
3 5 2
transplant immunosuppressive therapy,
963-965
allograft transplant rejection, 964-965
cervix, 964
decoy cells, 965
fine needle aspiration o f renal allograft,
964-965
lymphomas, 963-964
lymphoproliferative disorders, 963
urine cytology o f renal allograft, 965
transthoracic needle biopsy, diagnostic
accuracy, 303
transudates, effusions, 523
transurethral resection o f prostate (TURP),
968-969
trauma, central nervous system, 443
trichomonads
bacterial infections, 96
effusions, 543
key features, 66
and
Lep to tric h ia buccalis,
103
Trichom onas vag inalis,
92, 94
cervix, benign proliferative reactions, 149
Trichom onas vaginalis
, parasitic infection, 123-125
cytomorphologic features, 123-124
trichuriasis, parasitic infection, 125-126
T ric h u ris tric h iu ra
, 125
T ric h u ris tric h iu ra
, parasite, 125-126
Tripath FocalPoint device, cervical cytology
automation, 1030-1034
location-guided screening application,
1033-1034
primary screening application, 1030-1033
quality control application, 1030
triple test, breast cancer, 715-716
trophoblastic cells, pregnancy, 257
trophoblastic neoplasia, placenta, 267-268
trypsin digestion, 25
TSGs (tum or suppressor genes), 13, 14
TSH (thyroid-stimulating hormone), 634, 639,
640
tubal metaplasia
cellular changes, 96
defined, 214
endometrial cells, normal-appearing,
2 5 5
glandular cell lesions,
216,
230-231
tuberculosis
cervical, 99-100
effusions, 541
tuberculosis
(C o n tin u e d )
lymph nodes, 680
urinary tract, 415
tubular adenoma, 729
tum or markers
BRCA1 and BRCA2 genes, breast cancer,
13, 737-738, 761
CA 125 (ovarian cancer), 298
cytospins, 593
urinary tract, 434
tum or suppressor genes (TSGs), 13, 14
tumors
see
cancer
TURP (transurethral resection o f prostate),
968-969
tw o-hit hypothesis, hereditary cancer, 13
U
ulcerative colitis, 398
ulcers/ulceration
endocervical polyps, 236,
2 4 0
herpes simplex virus infection, 108
unusual uterine tumors, 267
ultrasound, 601
endoscopic, 374, 579
liver, 874
thyroid gland, 634
ureters
papillary carcinoma,
4 2 8
retrograde catheterization, 411
urethra, cancer of, 426-427
urinary tract
see also
bladder
atypia, 417
bladder cancer screening, 54, 409-410
calculi in, 417
cancer o f
see
urinary tract tumors
cytocentrifugation-based preparations,
410, 411
degenerative changes, 416
developmental abnormalities, 414
dysplasia, 417
endometriosis, 414
filtration techniques, 410, 411
hyperplasia, 417
iatrogenic changes, 417, 429-432
ilial conduits, cytology, 431
inflam m ation, nonspecific and bacterial,
414-415
intracytoplasmic and intranuclear
inclusions, 416-417
irradiation changes, 429,
431,
956
laser-induced changes, 429
non-neoplastic abnormalities, 414-417
renal allograft monitoring, 431-432
sampling techniques, 410-411, 995-997
upper collecting system of, 427,
4 2 8
, 429
urothelium
see
urothelium and
specialized lining
virus infections, 415-416
urinary tract tumors, 417-429
see also
bladder cancer; kidney cancer
adenocarcinoma, 424-426
carcinoma in situ, 422
in children, 942-945
diagnostic accuracy, 434-435
dysplasia, 421
grading schemes, 418, 434
papillary tum or grade I, 419-420,
4 2 8
urinary tract tumors
(C o n tin u e d )
papillary tum or grade II, 420,
4 2 8
papillary tum or grade III, 420-421
nonpapillary, 417, 422-424
papillary,
70, 71,
417-421
papilloma, 418-419
special techniques
blood group antigen predictors, 433
BTA stat/BTA Trak tests, 433
DNA methylation, 434
FISH, 433-434
flow cytometry, 432-433
Im m unoCyt test, 434
immunocytochemistry, 433
morphometry, 433
nuclear matrix protein, 433
telomerase, 434
tum or markers, 434
squamous cell carcinoma, 424
urethra, 426-427
W ilm s tum or
see
W ilm s tum or
(nephroblastoma)
urine
aspirates, 411
BKV genotype in, 415
blood in, 410
cytology, 54, 409, 410, 423, 432
o f renal allograft, 965
lubricant in,
414
sample collection, 410
smears o f fresh and fixed specimens, 411
renal allograft monitoring, 431
urothelial carcinoma
effusions, 555
nonpapillary, 417, 422-424
papillary,
70
,
71
, 420-421
renal pelvis, 842-843
urothelium and specialized lining
columnar cells, 412
histology, 411-412
norm al cells,
411
norm al cytology, 412-414
renal tubular epithelial cells, 412
superficial cells,
411
, 412-413
urothelial cells,
69, 412, 413
US-FNA (ultrasound FNA), 635, 653
Uterus
see also
endometrium
lymphomas, 266-267
prolapse of, 137
sarcomas, 266
trophoblastic neoplasia, 267-268
V
vacuolation, cytoplasmic, 268
vagina
atrophic epithelium of, 92
benign neoplasms/tumor-like
conditions, 282
clear cell carcinoma, 280,
28 1 ,
282
cysts, 279-280
diethylstilbestrol-related abnormalities,
280, 282
E m b ryo n a l rhabdom yosarcom a,
282-283
high PH of, 97
histology, 279
infectious and inflam m atory diseases, 279
melanomas,
2 8 4
1119
previous page 1102 ComprehensiveCytopathology 1104p 2008 read online next page 1104 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off